Clinical trials: Stage 2 Hypertension
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Pulmonary Arterial Hypertension
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=)…
- Trial name
- NCT03492177
- Testing
- selexipag (Uptravi)
- Where
- 34 sites in United States, Belarus and 14 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1015" and co-administration of "BR1015-1" and "BR1015-2" under fasting conditions in healthy volunteers
- Trial name
- NCT06008028
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Hypertension, Hyperlipidemia
A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin
This is a phase 1, open label, two-cohort, single-sequence, crossover study
- Trial name
- NCT02951962
- Testing
- Twynsta 80/5mg, Crestor 20mg
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Hypertension
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.
- Trial name
- NCT01260857
- Testing
- Aldazide
- Sponsor
- Pfizer
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Mild Hypertension
A Study in People With Mild Hypertension
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
- Trial name
- NCT00374855
- Testing
- PPAR alpha, Hydrochlorothiazide
- Where
- 10 sites in Sweden
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Uncontrolled Hypertension, Resistant Hypertension
A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients
SYH2072 is a highly selective aldosterone synthase inhibitor. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of SYH2072 tablets in patients with…
- Trial name
- NCT07911735
- Testing
- SYH2072 Tablets
- Volunteers
- 264 people
- Sponsor
- InnovStone Therapeutics Limited
Type 2 Diabetes
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
- Trial name
- NCT00376181
- Testing
- Pioglitazone and Azilsartan, Pioglitazone
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Hypertension
Amlodipine Prevents Morning Blood Pressure Surge Study
1. Study name:Amlodipine Prevents Morning Blood Pressure Surge Study 2. Study drugs:amlodipine (Norvasc®) and nifedipine GITS (Adalat®) 3.
- Trial name
- ARMORS (NCT01030081)
- Testing
- Amlodipine (Norvasc®), Nifedipine GITS (Adalat® XL 30
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine